Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Conditions:   Leukemia, Lymphocytic, Chronic, B-Cell;   Lymphoma, B-cell Marginal Zone;   Lymphoma, Non-Hodgkin;   Multiple Myeloma;   B-cell Lymphoma;   Waldenstrom Macroglobulinemia;   Lymphoma, Mantle-Cell Interventions:   Drug: LOXO-338;   Drug: Pirtobrutinib Sponsors:   Eli Lilly and Company;   Loxo Oncology, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials